POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)

Autor: Lunning, Matthew, Deger, Kristen A., Liu, Fei Fei, Elsada, Ahmed, Klijn, Sven L., Litkiewicz, Michal, Franco-Villalobos, Conrado, Sorensen, Sonja V.
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S228-S228
Databáze: ScienceDirect
Externí odkaz: